A Phase 1 Study of PD-1 Inhibition With Pembrolizumab Combined With JAK2 Inhibition in Triple Negative Breast Cancer

Trial Profile

A Phase 1 Study of PD-1 Inhibition With Pembrolizumab Combined With JAK2 Inhibition in Triple Negative Breast Cancer

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Ruxolitinib (Primary) ; Pembrolizumab
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Nov 2017 Planned initiation date changed from 31 Oct 2017 to 31 Jan 2018.
    • 28 Aug 2017 Planned initiation date changed from 1 May 2017 to 31 Oct 2017.
    • 15 Mar 2017 Planned primary completion date changed from 1 Feb 2020 to 1 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top